A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine [tick borne encephalitis vaccine] (free of protein-derived stabilizer) in study V48P4E1, five years after first booster immunization
Latest Information Update: 06 Jun 2007
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis
- Focus Pharmacodynamics
- Sponsors Novartis
- 06 Jun 2007 New trial record.